Zydus Lifesciences, Glenmark Pharmaceuticals and UltraTech Cement to see some action today

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), has invested in Feldan Therapeutics (Feldan), a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics. Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. 

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA is planning to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark’s Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women’s Health, Inc. and the company will begin distribution in May 2025.

UltraTech Cement has entered into Energy Supply Agreement and Share Subscription and Shareholders Agreement and to acquire 26% equity shares of AMPIN C&I Power Eight, a company engaged in generation and transmission of renewable energy. The acquisition is for the purposes of meeting the company’s green energy needs, optimising energy cost and comply with regulatory requirements for captive power consumption under electricity laws. 

Crest Ventures’ wholly owned subsidiary -- Crest Finserv (CFL) has incorporated a wholly owned subsidiary (WOS) namely, Crest Finserv Gift City IFSC (CFIFSCPL) on April 16, 2025. CFIFSCPL is incorporated with the objective to provide ‘Voice Broking’ services under the International Financial Services Centres Authority’s Ancillary Framework. 

Ace Software Exports has invested Rs 4 crore only in the Equity Shares of the AQE Techtools, a wholly owned subsidiary of the Company by way of subscription to the Rights Issue. Being a wholly owned subsidiary, there is no change in the shareholding percentage of the company in AQE Techtools, pursuant to this investment. 

Atishay has been successfully qualified and empanelled as a Business Partner with ITI, a Government of India Undertaking. The company has been empanelled under Class D in the following categories for Telecom and IT business opportunities: ICT-Based E-Governance; IT Networking and Management; and Software and Cloud-Based Solutions. This empanelment marks a significant milestone in the company’s strategic growth journey and affirms its competence in delivering robust, scalable, and innovative digital solutions. 

KFin Technologies (KFintech) has entered into a definitive agreement with Ascent Fund Services Pte (Ascent) to acquire controlling stake of 51% for $34.7 million, with a path to 100% ownership over the next five years. Post this transaction, the company will become the sole promoter of Ascent, and the residual 49% stake will be acquired in three equal tranches of 16.33% each after the end of fiscal year 2028, 2029, and 2030 respectively. The transaction is subject to customary regulatory approvals. The acquisition shall expedite the company’s entry into the fast growing and large market of global fund administration industry having more than $12 billion annual revenue pool.